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Background and objectives: Hyoscine butylbromide (HBB) is widely used in labor rooms. 
There have been many studies on the use of HBB during labor with conflicting results, involving 
both primiparous and multiparous women. The aim of this trial was to study the efficacy of 
HBB for shortening the first stage of labor in primiparous women.
Methods: The study was a randomized, double blind, controlled trial. Ninety-seven   primigravid 
term pregnant women in spontaneous labor received either hyoscine butylbromide or a   placebo 
intramuscularly once the women entered the active phase of labor. The primary outcome 
  measured was the duration of the first stage of labor. Secondary outcomes were the duration of 
the second and third stages of labor, blood loss at delivery, rate of cesarean section, and Apgar 
scores for the neonates.
Results: A total of 97 women yielded data for analysis. Of these, 45 women received the 
placebo and 52 received HBB. The mean duration of the first stage in the control group was 
215 minutes, compared with 165 minutes in the study group, representing a decrease of 23.3% 
(P = 0.001). There were no significant changes in the duration of the second (P = 0.063) or 
third (P = 0.0418) stages of labor, and no significant differences in blood loss or Apgar scores. 
There was a slightly higher (but statistically insignificant) rate of instrumental delivery in the 
control group, but no difference in the Cesarean section rate. There was a 60% reduction in 
opioid analgesic use in the HBB group.
Conclusion: HBB is effective in significantly reducing the duration of the first stage of labor, 
and is not associated with any apparent adverse maternal or neonatal outcomes.
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Introduction
The management of normal labor is both an art and a science. For decades, health 
  providers have worked to manage labor actively and safely, with the goal of shortening 
the duration of painful labor. Reduction of Cesarean sections and other fetal and 
maternal complications is also an important aspect of labor management.
The safety of active management of labor has been demonstrated by several 
  prospective randomized clinical trials involving over 3000 women.1 A shorter duration 
of labor from admission to delivery has also been consistently reported in numerous 
studies of women treated with the active management protocol.1–3
Hyoscine butylbromide (HBB) belongs to the parasympatholytic group of drugs 
and is a semisynthetic derivative of scopolamine. It is an effective antispasmodic 
drug without the untoward side effects of atropine. HBB is a quaternary ammonium 
  compound and has peripheral anticholinergic action, but no central action as it does Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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not cross the blood–brain barrier. HBB acts primarily 
by blocking the transmission of neural impulses in the 
intraneural parasympathetic ganglia of abdominal organs, 
apparently inhibiting cholinergic transmission in the synapses 
of the abdominal and pelvic parasympathetic ganglia, thus 
relieving spasms in the smooth muscles of gastrointestinal, 
biliary, urinary tract, and female genital organs, especially the 
cervico-uterine plexus, thus aiding cervical dilatation.4,5
Spasmolytic drugs are frequently employed in delivery 
rooms to overcome cervical spasms and thus reduce the 
duration of labor.6 HBB has been used to shorten the duration 
of labor in several hospitals in Saudi Arabia and elsewhere in 
the world.7–16 The mechanism by which it acts in the context 
of labor has not yet been elucidated, and evidence of its 
efficacy has been largely anecdotal.
Major studies have been carried out to evaluate the effects 
of the injectable or suppository form of HBB on cervical 
dilatation; a majority of these studies demonstrated the effi-
cacy of HBB in augmenting labor.7–16 However, a few studies 
showed no effect of HBB on accelerating labor.15 In addi-
tion, some studies also used oxytocin in active management 
of labor, which would certainly affect the duration of labor 
and increase bias in the results. Including both primiparous 
and multiparous patients can also affect the results, because 
the duration of labor is shorter in multiparous women, even 
without any method of augmentation. Therefore, in our 
study, we enrolled only primigravid women in spontaneous 
labor with no other means of augmentation.
The specific objectives of this study were to assess 
whether HBB is effective in hastening cervical effacement 
and dilatation, thus shortening the duration of the first stage of 
labor in primiparous women without labor augmentation. We 
also intended to determine whether the use of HBB in the first 
stage of labor has any associated increases in complications, 
such as an increase in blood loss or the rate of cesarean 
deliveries, or a decrease in neonatal Apgar scores.
Methods
The study was designed as a double blind, randomized, 
controlled clinical trial comparing two groups of women: 
one group received HBB, while the other (control) group 
received a placebo. Enrollment for this study commenced in 
January 2009 and was completed in January 2010.
Approval of this study was obtained prior to its onset 
from the Ethical Committee of the University of   Dammam. 
Women were recruited from the delivery room of our 
institution, and full informed consent was obtained. The 
consent form was signed by the patient after explaining the 
purpose of enrollment in the study, aimed at shortening the 
first stage of labor using HBB, and describing potential side 
effects. Adequate opportunity was provided for the women 
to voice any questions or concerns regarding the study.
The sample size was based on a pilot study of ten patients, 
which determined a mean duration of the first stage of 
labor of 220 minutes. A reduction of 55 minutes in the first 
stage of labor was determined to be clinically significant. 
A sample size of 88 patients in both groups was determined 
to be required to detect this difference, with a type I error of 
0.05 and a type II error of 0.20, to compensate for drop out 
cases and adjust for normality. A total of 110 women were 
initially enrolled.
Women included in the study were all 17 years or older, 
primiparous, had singleton pregnancies, had   vertex presenta-
tion at term (gestational age between 37–41 weeks + 6 days), 
and had no chronic or pregnancy-induced illnesses. None of 
the women had any contraindications to vaginal delivery, 
and all were in established,   spontaneous labor with either 
intact membranes or spontaneous rupture of membranes 
for less than 12 hours. Exclusion criteria included previous 
uterine scarring, malpresentation, antepartum hemorrhage, 
multiparity, twin pregnancy, induced delivery, any medical 
disease, oxytocin induction, prolonged premature rupture of 
the membrane (more than 12 hours), and epidural analgesia. 
Established labor was defined as the presence of regular 
uterine contractions (2–3 per 10 minutes) associated with 
progressive cervical effacement and dilatation.
Randomization was accomplished using cards. One 
hundred and twenty sequentially numbered, opaque, sealed 
envelopes were used containing 60 cards labeled as placebo 
and 60 cards labeled as HBB (as Buscopan®, Boehringer 
Ingelheim GmbH, Germany). All of the envelopes were 
mixed together randomly and placed in a box.
Once the patient was admitted in active labor, a history 
and physical examination was conducted by the attending 
physician. A partogram was maintained throughout labor 
and vaginal examinations were conducted and recorded 
every 2 hours. The drug was given only when the cervix 
was fully effaced and was dilated to 3–4 cm. The attending 
nurse was asked to complete a form detailing the duration 
of labor during the first, second, and third stages, the mode 
of delivery, maternal complications, and neonatal conditions 
at birth (Apgar score and weight).
After the physician prescribed HBB, the nurse attending 
the patient informed the nurse in charge of the shift, who 
selected a random card from the box; only she was aware of 
the contents of the syringe. Sterile syringes were prepared Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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by the nurse in charge according to the label on the card, 
without disclosing its contents to the staff or physician. 
She then enclosed the card inside the envelope and affixed 
it to the patient’s partogram after delivery. Each syringe 
  contained either 2 mL HBB (40 mg) or 2 mL normal saline. 
Both liquids are colorless; thus, the syringes containing 
the drug were indistinguishable from those containing the 
placebo.   Participants received the contents of the syringe as 
a single dose, given intramuscularly (IM). The patient and 
the caregivers were blinded as to whether the active drug or 
placebo was being administered. Routine amniotomy was 
performed for all women in established labor who were 
found to have cervical dilatation of $4 cm, and who had not 
had spontaneous rupture of membranes. Opioid analgesia 
was routinely given after the amniotomy (meperidine 
hydrochloride 100 mg IM and promethazine 25 mg IM).
Laboring mothers were monitored in bed, and   continuous 
electronic cardiotocography was conducted to monitor fetal 
wellbeing. The duration of the first stage was calculated from 
the time of cervical dilatation of 3–4 cm in active labor until 
a fully dilated cervix was observed upon vaginal   examination 
conducted every 2 hours. Oxytocin   augmentation was 
initiated if the initial progress of labor (as assessed through 
partographs) was unsatisfactory. These patients were 
excluded from the study. Intervention by instrumentation 
or cesarean delivery was dictated by the usual obstetric 
indications.
All data sheets (containing the raw data obtained during 
the study) were collected by the first investigator. The nurse 
in charge communicated directly with the first investigator 
via the assigned mobile telephone, available in the delivery 
room, for any needed clarifications.
Normally distributed data were expressed as means ± 
standard deviations (SDs), and noncontinuous data, 
such as   cervical dilation, was expressed as a median and 
  interquartile range. Data were tested for a normal distribu-
tion using the Kolmogorov–Smirnov test. Categorical data 
such as instrumental delivery, cesarean section, postpar-
tum   hemorrhage, and perineal tear were analyzed using 
the   chi-square test or Fisher’s exact test, as appropriate. 
An unpaired t-test was used for continuous data and the 
  Mann-Whitney U test (the nonparametric equivalent) was 
used for comparison of noncontinuous data. P , 0.05 was 
considered significant. Statistical analyses were performed 
using statistical software version 7 for Windows (StatSoft 
Inc, Tulsa, OK, USA).
The duration of the first, second, and third stages of 
labor were right-skewed on initial analysis. The values 
were natural log transformed to attain normalization; this 
normalization was subsequently confirmed using the one-
sample Kolmogorov–Smirnov test. The independent sample 
t-test and Mann-Whitney U test were then used to evaluate 
the significance of mean and median differences for both 
raw and transformed groups of data. Outliers were noted in 
both the blood loss data and Apgar scores; analyses with and 
without these outliers did not change the results.
Results
A total of 110 women consented to be enrolled in the study; 
however, 13 women met the exclusion criteria, such as a 
patient request for epidural analgesia or the need for o  xytocin 
in the first stage of labor. Thus, data for 97 women were 
  ultimately included for analysis. Of these, 45 women received 
the placebo and 52 received HBB.
Patients in both groups were 17–39 years old, with a 
median of 23.9 years in the HBB group and 24.4 years in the 
control group. The mean height and weight in the HBB group 
were 155.5 cm and 68.1 kg, respectively, and in the control 
group were 154.2 cm and 66.1 kg, respectively. The median 
gestational age was 39 weeks + 4 days in both the HBB and 
control groups. The two groups were comparable in cervical 
findings at the time of presentation and recruitment into the 
study, ie, all patients were 3–5 cm dilated with a median 
of 3 cm in both groups, with strong uterine contractions 
(Table 1).
The mean duration of the first stage in the control group was 
215 minutes, compared with 165 minutes in the HBB group 
(Figure 1), with a difference of 50 minutes. This represents a 
statistically significant decrease of 23.3% (P = 0.001; 95% CI 
32–115). The mean duration of the combined first and second 
stages of labor was also calculated and showed a statistically 
Table 1 Patient characteristics and incidence of labor
Characteristic Control  
group 
(n = 45)
Hyoscine 
butylbromide  
group 
(n = 52)
P
Age (years) 24.4 (5.36) 23.9 (4.04) 0.638
Height (cm) 154.2 (10.38) 155.5 (5.61) 0.762
Weight (kg) 66.1 (12.93) 68.1 (11.95) 0.458
gestational age (weeks) 39.4 (1.11) 39.4 (0.98) 0.683
Cervical dilatation (cm) 3 (3–4) 3 (3–4) 0.596
spontaneous rupture  
of the membrane  
(yes/no)
10/35 23/29 0.039*
Notes: For patient characteristics, data are expressed as means (sD – standard 
deviation);  for  cervical  dilation,  data  are  median  and  interquartile  range;  for 
spontaneous rupture of the membrane, data are numbers. *Significant difference 
between the two groups.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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significant difference (P , 0.001), with a mean duration of 
251 minutes (92 SD [standard deviation]) in the control group 
and 190 minutes (75 SD) in the HBB group, indicating a 24% 
reduction in the duration of labor from a 4 cm dilated cervix 
until full expulsion of the fetus (Table 2). There were no sig-
nificant changes in the durations of the second (P = 0.063) 
or third (P = 0.0418) stages of labor.
There were no significant differences in the cardiotoco-
graphic findings between the study and control group. There 
was no difference in associated blood loss between the 
groups; all of the data fell within an average range, with no 
cases of postpartum hemorrhage.
There was a slightly higher rate of instrumental delivery 
(15.3%, n = 6) in the control group versus 13% (n = 6) in 
the HBB group; however, the difference was not statistically 
significant. In addition, there was no significant increase in 
the cesarean rate among the women receiving HBB (9%) 
compared with the control group (6%; P = 0.721). There 
were three cesareans in the control group, one case due to 
failure to progress and two cases due to fetal distress, while 
in the HBB group there were five cases, two due to failure 
to progress and three due to fetal distress (Table 3).
Only 22 patients (40%) in the HBB group required 
opioid analgesia, while all of those in the control group did, 
a statistically significant indication of the efficacy of HBB as 
an analgesic in addition to its role in augmentation of labor 
(P , 0.001; Table 4).
There were no significant differences between the Apgar 
scores recorded at 1 and 5 minutes between the groups. Of 
97 neonates, five babies in the study group (including three 
neonates by cesarean) and eight babies in the control group 
(including two neonates by cesarean) had Apgar scores of 7–8 
at 1 minute. These babies were held in a nursery under obser-
vation for 24 hours and were discharged in good condition. 
The remaining 84 neonates had a score of 9 at 1 minute. 
The Apgar score was 8–10 at 5 minutes for all 97 babies, 
with all babies surviving. The drug was well tolerated by all 
neonates and no adverse effects were noted in either group 
(P = 0.380).
Discussion
HBB, in the form of Buscopan, has been used to shorten 
the duration of labor in several hospitals in Saudi Arabia. 
Interestingly, it was introduced and suggested by   midwives 
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Figure 1 Mean durations of the first, second, and third stages of labor in the control group (group 2) and the hyoscine butylbromide group (group 1). 
Notes: Vertical bars denote 0.95% confidence intervals. *P , 0.001 indicates a significant difference between the hyoscine butylbromide and control groups.
Table 2 Mean duration of first and second stage of labor
Stage of labor Control  
group 
(n = 45)
Hyoscine  
butylbromide  
group 
(n = 52)
P
First stage (minutes) 214 (79) 165 (67) ,0.001
second stage (minutes) 40 (34) 28 (20) 0.063
First + second stage 
(minutes)
251 (92) 190 (75) ,0.001
Note: Data are expressed as means (sD – standard deviation).Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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trained in India and the Philippines. It is used as an intravenous 
or intramuscular injection for active management of labor, 
to shorten labor and to overcome an edematous cervix. It is 
typically given with promethazine to sedate the patient to 
some degree and eliminate the need for further analgesia. 
Whereas its analgesic properties are likely negligible in the 
context of labor, its value lies in shortening the duration of 
the first stage of labor. Consequently, the overall time spent 
in pain by the laboring mother is reduced. Although its 
use in some hospitals in Saudi Arabia is fairly widespread, 
evidence for its efficacy in this population has been largely 
anecdotal.
A review of the literature produced several older and some 
recent studies relating to HBB and its use in labor. Few were 
randomized, double-blind studies, and none was conducted in 
an Arabian population similar to that of Saudi Arabia. Most 
of these studies have used the intramuscular route,7,9,10 with 
a few isolated studies using intravenous11,13 and suppository 
routes,12 including varying doses of 40 or 20 mg as a single 
or repeated dose. The results of this study support previous 
reports that HBB shortens the first stage of labor.
The primary strength of this study, in addition to being 
a randomized double blind controlled trail, is that it was 
limited to primigravid patients in spontaneous labor with 
the exclusion of patients receiving oxytocin and epidural 
analgesia from the final statistical analysis, as these factors 
may shorten or prolong labor, respectively.
The results of our study are important for several reasons. 
Potential benefits of reduced first stage duration include 
reduced duration of severe pain, incidence of chorioamni-
onitis, neonatal sepsis, and puerperal sepsis, all of which 
increase in women with prolonged labor. A reduced need 
for repeat doses of opioid analgesia, which is associated 
with neonatal respiratory depression, is also a substantial 
benefit of a shorter labor process. This is particularly true in 
regions where epidural analgesia is not widely available, and 
thus opioid medications are used with increased frequency 
to relieve labor pain in the first stage. Additionally, we are 
certain that any intervention that can safely reduce the amount 
of time spent in the painful process of parturition will be 
greatly appreciated by women.
The reduction in first stage duration may also prove to 
be of particular importance for women with a borderline 
placental reserve, oligohydramnios, or risk of prolonged 
variable deceleration during labor, as may be encountered in 
women with hypertension (both chronic and gestational) and 
in women with sickle cell anemia, which is quite   common in 
our population. Prolonged labor in these women may result in 
the fetoplacental reserves becoming depleted, with consequent 
signs of fetal distress and an increased rate of cesarean.
Our study demonstrated that HBB significantly reduces 
the duration of the first stage of labor. However, we also 
demonstrated that there was no statistical difference in the 
durations of the second and third stages of labor (Figure 1), 
implying that HBB primarily acts on the cervix rather than 
promoting uterine activity. This is important, as it   obviates 
the concern regarding an excessively rapid second stage, 
which can result in both maternal complications (such 
as increased risk of lacerations or vaginal hematoma, 
particularly in the primigravida) and neonatal complications 
(such as intracranial hemorrhage due to rapid, uncontrolled 
decompression of the fetal head at delivery). Of equal 
  significance, the average blood loss at delivery was identi-
cal in both groups (Table 3). This suggests that there is no 
adverse effect on the contractile ability of the uterus in the 
postpartum period, as might theoretically be anticipated 
based on its antiparasympathetic pharmacological activity.
The difference in the duration of the first stage of labor 
between the two groups in the trial was 50 minutes. However, 
the women were subjected to examinations at regular 2 hour 
intervals; thus, the error in measuring the length of the first 
stage may have been as much as ±1–±2 hours, rendering the 
clinical significance of the result marginal. To assess this 
possibility, we repeated the analysis using the combined first 
and second stage duration, and the results remained nearly 
the same, demonstrating a statistically significant difference 
Table 4 need for analgesia
Analgesia Control  
group 
(n = 45)
Hyoscine  
butylbromide  
group 
(n = 52)
P
Meperidine 45 22 ,0.001
no meperidine 0 30 –
Table 3 Outcome of delivery
Outcome Control  
group 
(n = 45)
Hyoscine 
butylbromide 
group 
(n = 52)
P
instrumental delivery  
(yes/no)
6/39 6/46 0.967
Cesarean section  
(yes/no)
3/42 5/47 0.721
Postpartum hemorrhage  
(yes/no)
0/45 0/52 0.000
Tear (yes/no) 0/45 2/50 0.497
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in duration between the HBB and placebo groups, with a 
mean 64 minute difference. Thus, any error in measurement 
of the first stage time was not contributory to the outcome 
of the study.
We did not attain the numbers we had initially aimed for 
due to the elimination of 13 women. However, even using 
a sample size of almost 50 women per arm of the study, we 
still achieved a power of over 90%. Another limitation in the 
study design was that patients’ acceptance was not assessed, 
a parameter that is as important as efficacy.
The difference in average Apgar scores for the infants in 
the two groups was not statistically significant (Table 3). The 
number of neonates with a lower Apgar score was greater in 
the control group, which is likely related to the use of opioids 
in 100% of these patients, causing mild respiratory depression 
in the neonate and a reduction in the Apgar score. This suggests 
that there were no clinically significant effects of HBB on the 
neonates for any of the major organ systems. Although the study 
was not sufficiently powered for absolute exclusion of fetal/
neonatal adverse effects, the initial examination of each infant, 
on which the Apgar scores were based, showed no discernible 
differences in the infants in the HBB group compared with the 
control group. There was also no difference in the incidence or 
severity of cardiotocographic changes intra-partum (decreased 
beat-to-beat variability and fetal tachycardia are potential 
adverse effects of HBB) or of neonatal tachycardia.
Hyoscine/scopolamine has an excellent safety profile 
and as such has been approved by the Food and Drug 
Administration in the USA for preoperative use in women 
scheduled for cesarean section. In addition, the drug is 
considered compatible with breastfeeding.11 We believe 
that the evidence from our study, taken in the context of 
other available evidence based information, justifies our 
assessment that the drug is safe and that there are no adverse 
effects associated with its use in this context.
Conclusion
Based on the results of our study, and noting the supportive 
data from similar clinical trials, we conclude that HBB is 
effective in significantly reducing the duration of the first 
stage of labor and reducing the need for further analgesia, and 
that it is not associated with any apparent adverse outcomes 
in the mother or neonate. Further long term evaluation will 
be necessary to fully evaluate the scope of benefits that this 
reduction may confer.
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